Amnio Technology, LLC is a global leader in the development and distribution of amniotic tissue allografts. Amniotic tissue contains extracellular matrix proteins, growth factors, cytokines, carbohydrates, hyaluronic acid, and other elements naturally present in amniotic fluid and tissue essential for fetal growth and development. Amnio Technology is committed to advancing the science and use of these unique allografts to improve quality of life for patients in need.Type your paragraph here.

​BONESUPPORT AB | Injectable bio-ceramic composite development

BONESUPPORT AB is a Scandinavian orthobiologics company that develops and markets CERAMENT ®, an innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection ...

Neo is transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for value based healthcare. Neo is the first thoracolumbar fusion system that is peri-operatively integrated and universally streamlined while still giving surgeons the same feel and functionality plus the additional capability to better control of the placement of bio-mechanical forces compared to conventional systems. Neo’s revolutionary technology can help reduce system complexity, lower processing costs, diminish delays/cancellations and decrease contamination/infection which supports lower risk, time efficiency and profitability for surgeons and hospitals.

"OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients."


Smith & Nephew supports healthcare professionals in more than 100 countries in their daily efforts to improve the lives of their patients.

They do this by taking a pioneering approach to the design of advanced medical products and services, by securing wider access to diverse technologies for more customers globally, and by enabling better outcomes for patients and healthcare systems.

They have leadership positions in:

-Orthopaedics Reconstruction - joint replacement systems for knees, hips and shoulders
-Trauma & Extremities - products that help repair broken bones

-Annual sales in 2015 were more than $4.6 billion.
-They are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)